Jeff Chiprin's most recent trade in Iradimed Corp was a trade of 1,150 Restricted Stock Units done . Disclosure was reported to the exchange on March 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Iradimed Corp | Jeff Chiprin | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2026 | 1,150 | 1,150 | - | - | Restricted Stock Units | |
| Iradimed Corp | Jeff Chiprin | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2025 | 996 | 996 (0%) | 0% | - | Common Stock | |
| Iradimed Corp | Jeff Chiprin | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2025 | 996 | 1,994 | - | - | Restricted Stock Units | |
| Iradimed Corp | Jeff Chiprin | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 97.38 per share. | 11 Dec 2025 | 309 | 687 (0%) | 0% | 97.4 | 30,090 | Common Stock |
| Iradimed Corp | Jeff Chiprin | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2024 | 2,990 | 2,990 | - | - | Restricted Stock Units | |
| Iradimed Corp | Chiprin Jeff | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2024 | 2,989 | 2,989 | - | - | Performance-based Restricted Stock Units |